Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer

Curr Med Chem. 2021;28(21):4088-4116. doi: 10.2174/0929867328666201125120422.

Abstract

Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.

Keywords: MTH1; NUDIX; SAMHD1; cancer; inhibitors.; treatment.

Publication types

  • Review

MeSH terms

  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Nucleotides*
  • SAM Domain and HD Domain-Containing Protein 1

Substances

  • Enzyme Inhibitors
  • Nucleotides
  • SAM Domain and HD Domain-Containing Protein 1
  • SAMHD1 protein, human